## ICMJE DISCLOSURE FORM

**Date:** 9/8/21

Your Name: David Burns

Manuscript Title: Epstein-Barr virus-associated lymphoproliferative disorders in immunosuppressed patients

Manuscript number (if known): AOL-20-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
	_		
7	Support for attending meetings and/or travel	Kite-Gilead, Novartis	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
44	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Descipt of any investor	V. None	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ase summarize the above o	onflict of interest in the fol	lowing hox.

Meeting attendance support from: Kite-Gilead, Novartis		

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: 5<sup>th</sup> August 2021

Your Name: Dr Sridhar Chaganti

Manuscript Title: Epstein-Barr virus-associated lymphoproliferative disorders in immunosuppressed patients

Manuscript number (if known): AOL-20-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_XNone	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Janssen	36 months  Grant for Tidal Study in 1 <sup>st</sup> lin PTLD treatment.
3	Royalties or licenses	_XNone	
4	Consulting fees	Kite-Gilead, Novartis, Celgene-BMS, Roche, Incyte, Takeda, Atara Bio	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Kite-Gilead, Novartis, Celgene-BMS, Roche, Incyte, Takeda, Atara Bio	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	Kie-Gilead, Novartis, Takeda, Celgene-BMS	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	_XNone	

## Please summarize the above conflict of interest in the following box:

Advisory board, consultancy, meeting attendance support from: Takeda, Novartis, Celgene/BMS, Kite/ Gilea Bio, Roche, Incyte.	ıd, Atara

Please place an "X" next to the following statement to indicate your agreement:

X_ I certify that I have answered	d every question and have	not altered the wording o	f any of the questions on this
form.	, 1	<b>.</b>	, , , , , ,